Information Library
Results for: White Papers - High-quality studies - Phase II/III
To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.
- Sort by:
- Recently Added
- Title
-
The Molecular Biomarker Revolution in Non-Small Cell Lung Cancer
June 23, 2011
In this new white paper Quintiles’ experts Christopher Ung, Jason Hill, Carrie Lee and Harish Dave review some of the most promising molecular pathways and targeted approaches for NSCLC, the critical role of diagnostics, and strategies to detect and address the emergence of resistance. -
Regulations for Clinical Studies in Pediatric Patients in the European Union
March 10, 2010
After the United States issued pediatric drug study requirements, the European Union (EU) passed a regulation that created major changes to clinical studies for pediatric -
New FDA Guidance on Antidiabetic Therapies
December 11, 2009
Understanding the FDA Guidance on Assessing Cardiovascular Risks for new Antidiabetic Therapies. Learn what FDA cardiac safety requirements may mean for your development program. -
Monitoring for Quality
May 22, 2008
Scott Cooley, Executive Director, Phase IIIb/IV Product Management, Quintiles, discusses innovative and traditional resources in a risk-based monitoring program.
Page 1 of 1 (4 results)
